Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

Viracta Therapeutics, Inc. Common Stock (VIRX)

Pharmaceutical Preparations

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

2533 S COAST HWY 101, SUITE 210
CARDIFF, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/25/2021

Market Cap

11,746,375

Shares Outstanding

38,630,000

Weighted SO

38,624,553

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

VINC --.--%

TCON --.--%

RLYB --.--%

TNYA --.--%

LYRA --.--%

TRVI --.--%

SQZ --.--%

TARA --.--%

ALXO --.--%

Beta

0.3360

Last Div

0.0000

Range

0.29-1.52

Chg

-0.0494

Avg Vol

495853

Mkt Cap

11746375

Exch

NASDAQ

Country

US

Phone

858 400 8470

DCF Diff

0.6913

DCF

-0.3428

Div Yield

0.0000

P/S

15.9165

EV Multiple

-0.0114

P/FV

1.4509

Div Yield %

0.0000

P/E

-0.2600

PEG

-0.0026

Payout

0.0000

Current Ratio

1.0845

Quick Ratio

1.0845

Cash Ratio

1.0473

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1027.1116

CCC

-1027.1116

Gross Margin

0.3808

Op Margin

-67.0732

Pretax Margin

-61.4295

Net Margin

-61.4295

Eff Tax Rate

0.0134

ROA

-1.4474

ROE

-2.6853

ROCE

-18.5324

NI/EBT

1.0000

EBT/EBIT

0.9159

EBIT/Rev

-67.0732

Debt Ratio

0.6008

D/E

2.3168

LT Debt/Cap

0.0000

Total Debt/Cap

0.6985

Int Coverage

-315.2866

CF/Debt

-2.0319

Equity Multi

3.8560

Rec Turnover

0.0000

Pay Turnover

0.3554

Inv Turnover

0.0000

FA Turnover

3.5825

Asset Turnover

0.0236

OCF/Share

-0.9704

FCF/Share

-0.9691

Cash/Share

1.1681

OCF/Sales

-51.8130

FCF/OCF

0.9987

CF Coverage

-2.0319

ST Coverage

-2.0319

CapEx Coverage

-749.7647

Div&CapEx Cov

-749.7647

P/BV

1.4509

P/B

1.4509

P/S

15.9165

P/E

-0.2600

P/FCF

-0.3076

P/OCF

-0.3082

P/CF

-0.3082

PEG

-0.0026

P/S

15.9165

EV Multiple

-0.0114

P/FV

1.4509

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 27, 20:44 Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues GlobeNewswire Inc. Dec 04, 08:30 Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

Revenue Product Segmentation